Ionis Pharmaceuticals Overview

  • Status
  • Public

  • Employees
  • 927

Employees

  • Stock Symbol
  • IONS

Stock Symbol

  • Investments
  • 20

  • Share Price
  • $40.91
  • (As of Wednesday Closing)

Ionis Pharmaceuticals General Information

Description

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).

Contact Information

Formerly Known As
Isis Pharmaceuticals, Isis Pharmaceuticals Inc
Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
NAS
Corporate Office
  • 2855 Gazelle Court
  • Carlsbad, CA 92010
  • United States
+1 (760) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ionis Pharmaceuticals Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$40.91 $41.54 $34.32 - $54.44 $6.05B 146M 1.13M -$2.56

Ionis Pharmaceuticals Financials Summary

In Thousands,
USD
TTM 31-Dec-2023 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 6,475,002 6,475,002 4,607,971 3,591,922
Revenue 787,647 787,647 587,367 810,456
EBITDA (235,870) (235,870) (233,080) (5,188)
Net Income (366,286) (366,286) (269,722) (28,597)
Total Assets 2,990,072 2,990,072 2,533,876 2,611,690
Total Debt 1,453,539 1,453,539 1,369,195 1,251,050
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Ionis Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Ionis Pharmaceuticals‘s full profile, request access.

Request a free trial

Ionis Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad cl
Drug Discovery
Carlsbad, CA
927 As of 2023
0000
00.000 0000-00-00
00000000000 0000

000000

nt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exerc
0000000000000
Pasadena, CA
000 As of 0000
00.000
00000000 00.000

000000

r adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna al
0000 000000000
Cambridge, MA
0000 As of 0000
00.00
00000000000 00.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Ionis Pharmaceuticals Competitors (46)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Arrowhead Pharmaceuticals Corporation Pasadena, CA 000 00.000 00000000 00.000
Moderna Formerly VC-backed Cambridge, MA 0000 00.00 00000000000 00.00
Dicerna Pharmaceuticals Formerly VC-backed Lexington, MA 000 00000 000000&0 00000
Regeneron Pharmaceuticals Formerly VC-backed Tarrytown, NY 00000 00.000 000000000000 00.000
Gilead Sciences Formerly VC-backed Foster City, CA 00000 000.00 0000
You’re viewing 5 of 46 competitors. Get the full list »

Ionis Pharmaceuticals Executive Team (21)

Name Title Board Seat Contact Info
Brett Monia Ph.D Chief Executive Officer & Board Member
Elizabeth Hougen Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
C. Bennett Ph.D Chief Scientific Officer & Executive Vice President
Hezekiah Blake Director & Head of Competitive Intelligence
Eugene Schneider MD Executive Vice President & Executive
You’re viewing 5 of 21 executive team members. Get the full list »

Ionis Pharmaceuticals Board Members (13)

Name Representing Role Since
000000 0000 Self Board Member 000 0000
0. 00000000 000 Ionis Pharmaceuticals Board Member 000 0000
00000 00000 00.0 Ionis Pharmaceuticals Chief Executive Officer & Board Member 000 0000
0000 000000 Self Board Member 000 0000
000000 00000 000 Ionis Pharmaceuticals Board Member 000 0000
You’re viewing 5 of 13 board members. Get the full list »

Ionis Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ionis Pharmaceuticals Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Ionis Pharmaceuticals‘s full profile, request access.

Request a free trial

Ionis Pharmaceuticals Investments & Acquisitions (20)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Aro Biotherapeutics 23-Nov-2021 00000 0000 000.00 Drug Discovery
Bicycle Therapeutics 09-Jul-2021 0000 000.00 Biotechnology
Akcea Therapeutics 12-Oct-2020 0000000000 00000 Biotechnology 00000 000
Empirico 20-Dec-2019 00000 0000 0000 Drug Discovery
Dynacure 10-Nov-2017 Early Stage VC Drug Discovery 00000 000
You’re viewing 5 of 20 investments and acquisitions. Get the full list »

Ionis Pharmaceuticals ESG

Risk Overview

Risk Rating

Updated March, 30, 2024

26.19 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 16,173

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 909

Rank

00.00

Percentile

Biotechnology

Subindustry

00 of 401

Rank

00.00

Percentile

To view Ionis Pharmaceuticals’s complete esg history, request access »

Ionis Pharmaceuticals Exits (12)

Company Name Exit Date Exit Type Exit Size Status Buyers
Dynacure 10-Nov-2017 00000 00000 00 Completed
  • 00000 000000000000
Dynacure 01-Oct-2016 000000000000000000 00000 Completed
  • 3 buyers
Regulus Therapeutics 04-Oct-2012 000 0000 Completed
  • 3 buyers
Altair Therapeutics 12-Nov-2009 00000 00000 00 0000 Completed
  • 5 buyers
Regulus Therapeutics 04-Mar-2009 Early Stage VC 0000 Completed
  • 2 buyers
You’re viewing 5 of 12 exits. Get the full list »

Ionis Pharmaceuticals FAQs

  • Who is the founder of Ionis Pharmaceuticals?

    David Ecker Ph.D is the founder of Ionis Pharmaceuticals.

  • Who is the CEO of Ionis Pharmaceuticals?

    Brett Monia Ph.D is the CEO of Ionis Pharmaceuticals.

  • Where is Ionis Pharmaceuticals headquartered?

    Ionis Pharmaceuticals is headquartered in Carlsbad, CA.

  • What is the size of Ionis Pharmaceuticals?

    Ionis Pharmaceuticals has 927 total employees.

  • What industry is Ionis Pharmaceuticals in?

    Ionis Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Ionis Pharmaceuticals a private or public company?

    Ionis Pharmaceuticals is a Public company.

  • What is Ionis Pharmaceuticals’s stock symbol?

    The ticker symbol for Ionis Pharmaceuticals is IONS.

  • What is the current stock price of Ionis Pharmaceuticals?

    As of 17-Apr-2024 the stock price of Ionis Pharmaceuticals is $40.91.

  • What is the current market cap of Ionis Pharmaceuticals?

    The current market capitalization of Ionis Pharmaceuticals is $6.05B.

  • What is Ionis Pharmaceuticals’s current revenue?

    The trailing twelve month revenue for Ionis Pharmaceuticals is $788M.

  • Who are Ionis Pharmaceuticals’s competitors?

    Arrowhead Pharmaceuticals, Moderna, Dicerna Pharmaceuticals, Regeneron Pharmaceuticals, and Gilead Sciences are some of the 46 competitors of Ionis Pharmaceuticals.

  • What is Ionis Pharmaceuticals’s annual earnings per share (EPS)?

    Ionis Pharmaceuticals’s EPS for 12 months was -$2.56.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »